 1,2,4-Triazoles |
| What is claimed is: 1. A compound of the formula: ##STR5## and non-toxic salts thereof, wherein R.... |
|
| Combating pests with substituted 3,6-diphenyl-3,4-dihydro-2H-1,3,5-oxadiazine-2,4-diones |
| What is claimed is: 1. An oxadiazine derivative of the formula ##STR8## in which R.sup.1 represents ... |
|
| 3-(1-Imidazolyl)-derivatives of 2,3-dihydro-4H-1-benzopyran |
| We claim: 1. Compounds having the general formula (I) ##STR89## wherein R is C.sub.1 -C.sub.6 alkyl;... |
|
| Pharmaceutical compositions effective against coronary heart disease and hypertension |
| I claim: 1. A pharmaceutical composition useful in treating coronary heart disease or hypertension ... |
|
| Composition for removing adhesives from polymeric film and process for using same |
| What is claimed is: 1. A process for separating an adhesive polymeric resin, from a polymeric film, ... |
|
| Sustained release, and comfortable opthalmic composition and method for ocular therapy |
| What is claimed is: 1. An ophthalmic composition, comprising: a) at least one basic active; b) a ... |
|
| Bactericidal formulations for use in veterinary medicine |
| We claim: 1. A method of treating mycoplasmotic and bacterial infections in fowl which comprises ... |
|
| 1-(5-Amino-4H-1,2,4-triazol-3-yl)-4-substituted-piperazines |
| OF THE INVENTION The novel compounds of the present invention are obtainable as crystalline ... |
|
| 6-C.sub.1-4 Alkyl-7-phenyl or substituted phenyl-1,6-naphthyridine-5(6H)-ones |
| What is claimed is: 1. A compound of the formula ##STR19## or a pharmaceutically acceptable acid ... |
|
| Novel prostaglandins |
| OF THE INVENTION Also embraced within the scope of the present invention are the non-toxic, ... |
|
|
Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors
| Details |
Inventors: Garfield, Robert E.; Chwalisz, Krzysztof; Bukowski, Radoslaw; Yallampalli, Chandra;
Assignee: Schering Aktiengesellschaft (DE); Board of Regents, University of Texas (Austin, TX)
Primary Examiner: Lankford, Jr.; Leon B.
Assistant Examiner: Tate; Christopher R.
Attorney, Agent or Firm: Miller, White, Zelano & Branigan, P.C.
The symptoms of the climacterium are ameliorated by the administration to an afflicted individual one or both of a nitric oxide substrate and/or nitric acid donor, alone or optionally in combination with a progestin or, in the case of a non-pregnant female, either a progestin or an estrogen or both. |
|
DETAILED DESCRIPTION In a method aspect, this invention relates to a method of treating the climacterium symptoms in a non-pregnant female or in a male mammal which comprises administering to an individual manifesting the symptoms thereof one or both of a nitric oxide donor, alone or in further combination with a progestin, or, in the case of a female mammal, in further combination with one or both of a progestin and an estrogen, or in the case of a male mammal, in further combination with an androgen in amounts effective to ameliorate the symptoms thereof, the amount of the estrogen being bioequivalent to approximately 2 mg per day of estradiol (Progynova.
RTM.
, Schering), and the amount of the progestational agent administered being bioequivalent to 50-300 mg of injected progesterone and the amount of the nitric oxide synthase substrate, nitric oxide donor or both being effective to, respectively, either raise the blood level of circulating L-arginine in a pregnant female to whom the composition is administered to at least about 10-50 nmole above the normally 50-100 nmole circulating levels or raise nitric oxide donor levels -to about 1-100 nmolar (nanamolar).
In a product aspect, this invention relates to a pharmaceutical composition comprising at least one of the nitric oxide synthase substrate and a nitric oxide donor, alone or in further combination with one or more of a estrogen and/or progestin with the amount of the estrogen being bioequivalent to about 2 mg of estradiol (e.
g.
, Progynova.
RTM.
, Schering) with the amount of the estrogen being bioequivalent to 50-300 mg of injected progesterone and the amount of the nitric oxide synthase substrate, a nitric oxide donor or both per unit dosage being effective to, respectively, either raise the blood level of circulating L-arginine to at least about 10-50 nmole above the normally 50-100 nmolar circulating levels or raise the nitric oxide donor levels to about 1 to 1000 nmolar.
DETAILED DISCLOSURE The methods of this invention treat climacterium (climacteric symptoms) in a menopausal/ postmenopausal mammal, e
|
| Related patents |
|
|
Microbial hair tonic composition
We claim: 1. A microbial hair treatment composition comprising 10.sup.6 to 10.sup.8 cells/ml of cultured living Staphylococcus capitis and a suitable solvent. 2. The ...
|
|
|
Hair treating composition
OF THE INVENTION The formulation of 9 parts d-panthenyl ethyl ether and 1 part d-panthenol can be incorporated in hair conditioning or treating compositions in an ...
|
|
|
Hair cosmetic composition
We claim: 1. A composition of matter in the form of a solution, comprising: (a) a solvent including ethanol; (b) a hair-growing component which is at least one compound ...
|
|
|
Anti-thrombogenic, anti-microbial compositions containing heparin
OF THE INVENTION The compositions of the present invention are first dissolved in solvent mixtures that are co-solvents for the mixtures of non-volatile components and ...
|
|
|
Derivative-compound-conjugates and pharmaceutical compositions comprising same
OF THE INVENTION The introduction of molecules of diagnostic, prophylactic, or therapeutic interest across body surfaces and/or into cells requires the transversal of ...
|
|
|
Vincamine derivatives and process for the preparation of vincamine and derivatives thereof
Having now described our invention what we claim as new and desire to secure by Letters Patent is: 1. 20-Deethyl-apovincamine, having the formula: ##SPC7## under its ...
|
|
|
Naphthyridine derivatives and their use as anti-bacterials
What we claim is: 1. A 1,8-naphthyridine compound of the formula ##STR9## wherein R is vinyl or 2-fluoroethyl, R.sub.1 and R.sub.2 are the same or different and each ...
|
|
|
Indole derivatives
We claim: 1. A compound of formula (I) ##STR11## wherein R.sup.1 and R.sup.2 each represents a hydrogen atom or a C.sub.1-6 alkyl group, Z represents a ring selected ...
|
|
|
4-(3-(4-Quinolyl)propyl)piperidines, their preparation and their use as medicines
What is claimed is: 1. A method for the treatment of a mammal afflicted with a disturbance in the functioning of serotoninergical systems which comprises administering ...
|
|
|
Derivatives of 1-(2-,3- or 4-quinolyl)-2- or -3-(2- or 3-piperidyl or -pyrrolidinyl) ethanone or propanone, and their utilization as antiarrhythmics, anticonvulsivants and for the treatment of anxiety
What is claimed is: 1. Compounds of the formula: ##STR30## in which R is fixed in position 2 or 4 on the cycle of the quinoline and represents a phenyl, pyridyl or ...
|
|
|
Vasodialators 
